John S. Williamson

John S. Williamson

Auto-generated profile, based on publicly available information

John S. Williamson

University of Mississippi

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
EME. M.F. Muri
E. M.F. Muri
MNM. J. Nieto
M. J. Nieto
RSR. D. Sindelar
R. D. Sindelar
JWJ. S. Williamson
J. S. Williamson
A variety of hydroxamic acid derivatives have recently been touted for their potential use as inhibitors of hypertension, tumor growth, inflammation, infectious agents, asthma, arthritis, and more. Here we provide a comprehensive review of the basic medicinal chemistry and pharmacology of hydroxamic acid derivatives that have been examined as inhibitors of zinc metalloproteases, matrix metalloproteinases, leukotriene A4 hydrolases, ureases, lipoxigenases, cyclooxygenases, as well as peptide deformilases.

1 February 2004 in Tetrahedron
Verified
Journal Article
Closed access
BMBruhaspathy Miriyala
Bruhaspathy Miriyala
SBSukanta Bhattacharyya
Sukanta Bhattacharyya
JWJohn S Williamson
John S Williamson

1 February 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SKSuvarna Kini
Suvarna Kini
ABAnilchandra R. Bhat
Anilchandra R. Bhat
BBByron Bryant
Byron Bryant
JWJohn S. Williamson
John S. Williamson
FDFranck Dayan
Franck Dayan

1 March 2016 in Advances in Nutrition
Verified
Journal Article
Open access
PDF file
BOBa Orkin
Ba Orkin
AKAdam J Kuszak
Adam J Kuszak
JWJohn S Williamson
John S Williamson
DHD Craig Hopp
D Craig Hopp
JBJoseph M Betz
Joseph M Betz
Inconsistent and contradictory results from nutrition studies conducted by different investigators continue to emerge, in part because of the inheren

1 September 2001 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MLM. S. Levi
M. S. Levi
RBR. F. Borne
R. F. Borne
JWJ. S. Williamson
J. S. Williamson
Abstract: In the late 20th century, the treatment of cancer began to include its prevention. Today, compounds exist that will lower the risk of developing certain types of cancer. This has been demonstrated in studies where chemically induced tumor growth has been slowed or reversed. Anti-inflammatory compounds having chemopreventive activity are piroxicam, sulindac, aspirin, celecoxib and curcumin. The selective estrogen receptor modulators, tamoxifen and raloxifene, are beneficial in the prevention of estrogendependent tumors. Retinoids, vitamin A derivatives, such as targretin and fenretinide are useful in the prevention of tumors. Compounds containing sulfur, such as sulforaphane and oltipraz, are even useful as radioprotective agents. The steroid dehydroepiandosterone can inhibit experimental carcinogenesis. All of these chemical classes provide a start for the medicinal chemist to design more effective chemopreventive agents. The biomarkers used to determine the chemopreventive activity of new compounds are quite often activities of enzymes. The identification of those individuals at high risk is still in its infancy and presents a troubling dilemma.

1 June 2004 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
IPI. A. Parshikov
I. A. Parshikov
KMK. M. Muraleedharan
K. M. Muraleedharan
MAMitchell Avery
Mitchell Avery
JWJ. S. Williamson
J. S. Williamson